Segment Reporting

3 Months Ended

Mar. 31, 2025

Segment Reporting

Segment Reporting

Note 18 – Segment Reporting

The Company adopted ASU 2023-07 during the year ended December 31, 2024 retrospectively to all periods presented in the consolidated financial statements. The Company has one reportable segment managed on a consolidated basis by the Chief Executive Officer (CEO) who is the chief operating decision maker (“CODM”). In identifying one reportable segment, the Company considered the basis of organization for the design and development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.

The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance and decides how to allocate resources based on consolidated net loss as reported in the consolidated statements of operations and comprehensive loss. There are no other expense categories regularly provided to the CODM that are not already included in the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as cash, cash equivalents and money market accounts.

Summary of segment net loss, including significant segment expenses were as follows:

	Three Months Ended March 31,
	2025		2024
	Successor		Predecessor
Revenue	$	—	$	26
Less:
Cost of revenue		253		542
Research and development		3,659		3,469
Selling, general, and administrative		3,485		4,830
Other income (expense), net		(316)		797
Net loss	$	(7,713)	$	(8,018)